The global contraceptive market was estimated at USD 27.03 billion in 2021 and it is expected to surpass around USD 45.8 billion by 2030, poised to grow at a CAGR of 6.03% from 2022 to 2030.
The growing prevalence of Sexually Transmitted Infections (STIs), especially HIV, and the introduction of new products exhibiting improved efficacy is expected to drive the industry growth during the forecast period. The presence of high unmet contraceptive needs coupled with the implementation of favorable government policies is expected to significantly contribute to market growth. The government spending on contraceptives is growing rapidly.
This is expected to drive the growth of the market over the forecast period. According to the Family Planning 2020 Women at the Center report, Australia provided USD 22.2 million in bilateral family planning funding for the 2017 - 2018 fiscal year. The U.S. provided USD 630.6, the U.K. provided USD 292.2, Canada provided USD 81.8, and Germany provided USD 51.3 in bilateral family planning funding for the 2017 - 2018 fiscal year. The COVID-19 pandemic has negatively impacted the global industry. The negative impact can be attributed to the supply-chain disruption, and decline in demand for sexual and reproductive health services globally.
As per the Impact of COVID-19 on access to contraceptives in the LAC region by UNFPA, in Brazil, around 195,658 public-sector users were unable to access contraceptives with moderate disruption for six months during the pandemic, and around 97,829 public-sector users were unable to access contraceptives with low disruptions for three months, and around 391,316 public-sector users were unable to access contraceptives with high disruptions for twelve months. The industry is highly competitive with the presence of many major players. Companies are majorly investing in R&D and are adopting other strategies including M&As and expanding product pipelines. For instance, in April 2021, FDA approved a combination tablet of estetrol and drospirenone
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 27.03 billion |
| Revenue Forecast by 2030 | USD 45.8 billion |
| Growth rate from 2022 to 2030 | CAGR of 6.03% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Product, region |
| Companies Covered |
Bayer AG; China Resources Zizhu Pharmaceutical Co., Ltd. (CR Zizhu); Cupid Ltd.; Helm AG; Church & Dwight; Organon Group Of Companies; Pfizer Inc.; Viatris (Mylan); Abbvie, Inc.; Afaxys, Inc.; Agile Therapeutics; Janssen Pharmaceuticals, Inc.; Veru, Inc. |
Product Insights
Based on products, the global industry has been segmented into contraceptive drugs and contraceptive devices. The contraceptive devices segment dominated the industry with the largest revenue share of more than 35.2% in 2021. This is attributed to an increase in the awareness level of STDs and the efficiency of condoms to prevent infections, including HIV. In a recent study, subdermal implants have been identified to have an immense potential to meet the requirement of women for family planning. The contraceptive device segment is further sub-segmented into condoms, subdermal implants, IUDs, vaginal rings, and diaphragms.
The condoms segment held the largest share in 2021 owing to the rising demand in the regions of Europe and the Asia Pacific. The growth can also be attributed to the demand from the public sector source. According to the Family Planning Report 2021 report, around 378.1 million units of condoms were supplied by the Department of Health & Family Welfare in India. The contraceptive drugs segment is expected to witness lucrative growth during the forecast period. The segment is further sub-segmented into contraceptive pills, patches, and injectables. The contraceptive pill segment held the largest share of the segment in 2021.
The growth is attributed to the increased procurement volumes by public-sector organizations. As per the Family Planning 2021 report by Clinton Health Access Initiative, the market volumes for contraceptive pills including combined hormonal contraceptive and progestin-only pills accounted for around 201 million FP2020 market volumes. These pills are more affordable compared to contraceptive devices. As per the article published in The Lancet, around 14.8% of the total contraceptive prevalence in 2019 was attributed to contraceptive pills.
Regional Insights
North America dominated the global industry in 2021 with the maximum revenue share of more than 32.90% and is expected to maintain its position throughout the forecast period owing to the high incidence of abortion, rising population of women within the age group of 15-44 years, and high patient awareness levels in the region. The launch of generic and low-cost drugs and devices has also led to an increase in the demand for contraceptives by teenagers. In April 2022, Reckitt Benckiser launched a new condom category, Durex Intense. Asia Pacific is projected to witness the fastest CAGR during the forecast period.
The growth can be attributed to the rising number of government initiatives, growing demand for population control, and a decrease in the unintended pregnancy rate. According to the Center for Reproductive Rights, around 53.8 million unintended pregnancies occur every year in Asia, and around 65% of those are abortion cases. The contraception prevalence rate among married adolescents in Asia is around 41%. Europe held a significant market share in 2021 due to suitable reimbursement scenarios for the use of contraceptives.
According to the Center for Reproductive Rights, Access to Contraceptives in European Union Report, in Germany, IUDs, emergency contraception, and hormonal contraceptives with a prescription are covered under the mandatory health insurance scheme for females under the age of 18. There is a 10% co-payment for women aged 18 to 19 years of age with a capped value of 10 euros per prescription. Contraceptives are covered under the scheme for women aged 20 years and above when intended for other reasons apart from the prevention of pregnancy.
Chapter 1. Introduction
1.1.Research Objective
1.2.Scope of the Study
1.3.Definition
Chapter 2. Research Methodology
2.1.Research Approach
2.2.Data Sources
2.3.Assumptions & Limitations
Chapter 3. Executive Summary
3.1.Market Snapshot
Chapter 4. Market Variables and Scope
4.1.Introduction
4.2.Market Classification and Scope
4.3.Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5.COVID 19 Impact on Contraceptive Market
5.1. COVID-19 Landscape: Contraceptive Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4.Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1.Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2.Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1.List of Suppliers
7.1.3.2.List of Buyers
Chapter 8. Global Contraceptive Market, By Product
8.1.Contraceptive Market, by Product Type, 2017-2030
8.1.1. Contraceptive Drugs
8.1.1.1.Market Revenue and Forecast (2017-2030)
8.1.2. Contraceptive Devices
8.1.2.1.Market Revenue and Forecast (2017-2030)
Chapter 9. Global Contraceptive Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Product (2017-2030)
9.1.2. Market Revenue and Forecast, by Technique (2017-2030)
9.1.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.1.4. Market Revenue and Forecast, by End-use (2017-2030)
9.1.5. U.S.
9.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.1.5.2. Market Revenue and Forecast, by Technique (2017-2030)
9.1.5.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.1.5.4. Market Revenue and Forecast, by End-use (2017-2030)
9.1.6. Rest of North America
9.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
9.1.6.2. Market Revenue and Forecast, by Technique (2017-2030)
9.1.6.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.1.6.4. Market Revenue and Forecast, by End-use (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.2. Market Revenue and Forecast, by Technique (2017-2030)
9.2.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.2.4. Market Revenue and Forecast, by End-use (2017-2030)
9.2.5. UK
9.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.5.2. Market Revenue and Forecast, by Technique (2017-2030)
9.2.5.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.2.5.4. Market Revenue and Forecast, by End-use (2017-2030)
9.2.6. Germany
9.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.6.2. Market Revenue and Forecast, by Technique (2017-2030)
9.2.6.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.2.6.4. Market Revenue and Forecast, by End-use (2017-2030)
9.2.7. France
9.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.7.2. Market Revenue and Forecast, by Technique (2017-2030)
9.2.7.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.2.7.4. Market Revenue and Forecast, by End-use (2017-2030)
9.2.8. Rest of Europe
9.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.8.2. Market Revenue and Forecast, by Technique (2017-2030)
9.2.8.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.2.8.4. Market Revenue and Forecast, by End-use (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.2. Market Revenue and Forecast, by Technique (2017-2030)
9.3.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.3.4. Market Revenue and Forecast, by End-use (2017-2030)
9.3.5. India
9.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.5.2. Market Revenue and Forecast, by Technique (2017-2030)
9.3.5.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.3.5.4. Market Revenue and Forecast, by End-use (2017-2030)
9.3.6. China
9.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.6.2. Market Revenue and Forecast, by Technique (2017-2030)
9.3.6.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.3.6.4. Market Revenue and Forecast, by End-use (2017-2030)
9.3.7. Japan
9.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.7.2. Market Revenue and Forecast, by Technique (2017-2030)
9.3.7.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.3.7.4. Market Revenue and Forecast, by End-use (2017-2030)
9.3.8. Rest of APAC
9.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.8.2. Market Revenue and Forecast, by Technique (2017-2030)
9.3.8.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.3.8.4. Market Revenue and Forecast, by End-use (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.2. Market Revenue and Forecast, by Technique (2017-2030)
9.4.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.4.4. Market Revenue and Forecast, by End-use (2017-2030)
9.4.5. GCC
9.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.5.2. Market Revenue and Forecast, by Technique (2017-2030)
9.4.5.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.4.5.4. Market Revenue and Forecast, by End-use (2017-2030)
9.4.6. North Africa
9.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.6.2. Market Revenue and Forecast, by Technique (2017-2030)
9.4.6.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.4.6.4. Market Revenue and Forecast, by End-use (2017-2030)
9.4.7. South Africa
9.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.7.2. Market Revenue and Forecast, by Technique (2017-2030)
9.4.7.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.4.7.4. Market Revenue and Forecast, by End-use (2017-2030)
9.4.8. Rest of MEA
9.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.8.2. Market Revenue and Forecast, by Technique (2017-2030)
9.4.8.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.4.8.4. Market Revenue and Forecast, by End-use (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.5.2. Market Revenue and Forecast, by Technique (2017-2030)
9.5.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.5.4. Market Revenue and Forecast, by End-use (2017-2030)
9.5.5. Brazil
9.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.5.5.2. Market Revenue and Forecast, by Technique (2017-2030)
9.5.5.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.5.5.4. Market Revenue and Forecast, by End-use (2017-2030)
9.5.6. Rest of LATAM
9.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
9.5.6.2. Market Revenue and Forecast, by Technique (2017-2030)
9.5.6.3. Market Revenue and Forecast, by Monitoring Method (2017-2030)
9.5.6.4. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 10.Company Profiles
10.1.Bayer AG
10.1.1.Company Overview
10.1.2.Product Offerings
10.1.3.Financial Performance
10.1.4.Recent Initiatives
10.2.China Resources Zizhu Pharmaceutical Co., Ltd. (CR Zizhu)
10.2.1.Company Overview
10.2.2.Product Offerings
10.2.3.Financial Performance
10.2.4.Recent Initiatives
10.3.Cupid Ltd.
10.3.1.Company Overview
10.3.2.Product Offerings
10.3.3.Financial Performance
10.3.4.Recent Initiatives
10.4.Helm AG
10.4.1.Company Overview
10.4.2.Product Offerings
10.4.3.Financial Performance
10.4.4.Recent Initiatives
10.5.Church & Dwight
10.5.1.Company Overview
10.5.2.Product Offerings
10.5.3.Financial Performance
10.5.4.Recent Initiatives
10.6.Organon Group Of Companies
10.6.1.Company Overview
10.6.2.Product Offerings
10.6.3.Financial Performance
10.6.4.Recent Initiatives
10.7.Pfizer Inc.
10.7.1.Company Overview
10.7.2.Product Offerings
10.7.3.Financial Performance
10.7.4.Recent Initiatives
10.8.Viatris (Mylan)
10.8.1.Company Overview
10.8.2.Product Offerings
10.8.3.Financial Performance
10.8.4.Recent Initiatives
10.9.Abbvie, Inc.
10.9.1.Company Overview
10.9.2.Product Offerings
10.9.3.Financial Performance
10.9.4.Recent Initiatives
10.10.Afaxys, Inc.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11.Research Methodology
11.1.Primary Research
11.2.Secondary Research
11.3.Assumptions
Chapter 12.Appendix
12.1.About Us
12.2.Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers